Daijiworld Media Network - New Delhi

New Delhi, Nov 5: India has achieved a major milestone in medical science with NexCAR19, the world’s first humanised CAR-T (Chimeric Antigen Receptor T-cell) therapy, which has made gene-based cancer treatments both affordable and accessible without compromising on quality or patient safety, the Ministry of Science and Technology said on Wednesday.

Developed by ImmunoACT, a gene therapy company incubated at IIT Bombay, NexCAR19 is a prescription therapy for relapsed or refractory B-cell Non-Hodgkin’s Lymphoma and B-cell Acute Lymphoblastic Leukaemia, where frontline or standard treatments have failed. The therapy uses a lentiviral vector for gene modification.

“NexCAR19, India’s first living drug, has made gene therapies both affordable and accessib

See Full Page